Ascelia Pharma AB (publ) - Asset Resilience Ratio

Latest as of September 2021: 0.00%

Ascelia Pharma AB (publ) (ACE) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ACE total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

Skr365.04 Million

≈ $39.28 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Ascelia Pharma AB (publ)'s Asset Resilience Ratio has changed over time. See Ascelia Pharma AB (publ) (ACE) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Ascelia Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACE stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Ascelia Pharma AB (publ) maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Ascelia Pharma AB (publ) Industry Peers by Asset Resilience Ratio

Compare Ascelia Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Ascelia Pharma AB (publ) (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Ascelia Pharma AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.00%	Skr1.00K ≈ $107.62	Skr87.07 Million ≈ $9.37 Million	--
2020-12-31	0.00%	Skr0.00 ≈ $0.00	Skr255.37 Million ≈ $27.48 Million	--
2019-12-31	30.26%	Skr75.71 Million ≈ $8.15 Million	Skr250.23 Million ≈ $26.93 Million	+4.14pp
2018-12-31	26.12%	Skr75.08 Million ≈ $8.08 Million	Skr287.42 Million ≈ $30.93 Million	+26.18pp
2016-12-31	-0.06%	Skr-47.00K ≈ $-5.06K	Skr80.39 Million ≈ $8.65 Million	--

pp = percentage points

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$40.96 Million

Skr380.61 Million SEK

Market Cap Rank

#22609 Global

#421 in Sweden

Share Price

Skr3.00

Change (1 day)

+2.04%

52-Week Range

Skr2.60 - Skr5.10

All Time High

Skr900.24